Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Reducing Episodic Cluster Headaches: Focus on Galcanezumab

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Neuroimaging Of Cold Allodynia Reveals A Central Disinhibition Mechanism Of Pain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Management of chronic pain after hernia repair

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Neck/shoulder function in tension-type headache patients and the effect of strength training

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The chronobiology of migraine: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The involvement of calcitonin gene-related peptide in migraine and cluster headache has led to the recent development of new therapies. Galcanezumab, a novel monoclonal antibody targeting the calcitonin gene-related peptide, is approved for the migraine prevention and has recently been tested for the prevention of cluster headache. Two clinical trials have been conducted to investigate the efficacy and safety of galcanezumab in episodic cluster headache and chronic cluster headache. While efficacy endpoints were not met in the chronic subtype, galcanezumab reduced the weekly frequency of attacks in patients with episodic cluster headaches. In both studies, the antibody was well tolerated. This review summarizes and critically reviews the available data regarding the rationale behind targeting the calcitonin gene-related peptide with galcanezumab for the prevention of cluster headache.

OriginalsprogEngelsk
TidsskriftJournal of Pain Research
Vol/bind13
Sider (fra-til)1591-1599
Antal sider9
ISSN1178-7090
DOI
StatusUdgivet - 2020

Bibliografisk note

© 2020 Pellesi et al.

ID: 60627248